| Names | |
|---|---|
| Preferred IUPAC name | 1-cyclopropyl-7-(4-ethylpiperazin-1-yl)-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid |
| Other names | Baytril Enrocin Enroxil Quinoloks Enrolet |
| Pronunciation | /ɛnˌroʊ.fləˈksə.sɪn/ |
| Identifiers | |
| CAS Number | 93106-60-6 |
| Beilstein Reference | Beilstein 80055 |
| ChEBI | CHEBI:47975 |
| ChEMBL | CHEMBL1255 |
| ChemSpider | 86544 |
| DrugBank | DB01182 |
| ECHA InfoCard | 03b450b2-cfa4-435d-8a5f-9a9bfacb83f8 |
| EC Number | 3.5.2.10 |
| Gmelin Reference | 671502 |
| KEGG | C07492 |
| MeSH | D018925 |
| PubChem CID | 71188 |
| RTECS number | QJ1235000 |
| UNII | M5BYM1K0QJ |
| UN number | UN2811 |
| Properties | |
| Chemical formula | C19H22FN3O3 |
| Molar mass | 359.4 g/mol |
| Appearance | Light yellow to yellow crystalline powder |
| Odor | Odorless |
| Density | D = 1.329 g/cm3 |
| Solubility in water | Slightly soluble in water |
| log P | -0.41 |
| Vapor pressure | 6.7 x 10^-9 mm Hg |
| Acidity (pKa) | 6.19 |
| Basicity (pKb) | 7.70 |
| Refractive index (nD) | 1.613 |
| Dipole moment | 4.87 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 0.475 kJ/mol·K |
| Std enthalpy of formation (ΔfH⦵298) | -831.2 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -589.8 kJ·mol⁻¹ |
| Pharmacology | |
| ATC code | J01MA90 |
| Hazards | |
| Main hazards | May cause allergic skin reaction; harmful if swallowed; causes serious eye irritation. |
| GHS labelling | GHS05, GHS07 |
| Pictograms | GHS05,GHS07 |
| Signal word | Warning |
| Hazard statements | H302: Harmful if swallowed. H315: Causes skin irritation. H319: Causes serious eye irritation. H335: May cause respiratory irritation. |
| Precautionary statements | Keep out of reach of children. Avoid contact with skin, eyes, and clothing. Wash thoroughly with soap and water after handling. If swallowed, seek medical advice immediately and show this container or label. |
| NFPA 704 (fire diamond) | 2-1-0 |
| Flash point | Flash point: 230 °C |
| Lethal dose or concentration | LD50 (oral, rat): 5000 mg/kg |
| LD50 (median dose) | LD50 (median dose) of Enrofloxacin: 5000 mg/kg (oral, rat) |
| NIOSH | QLT9000000 |
| PEL (Permissible) | PEL not established |
| REL (Recommended) | 5 mg/kg |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds | Ciprofloxacin Norfloxacin Ofloxacin Levofloxacin Danofloxacin Marbofloxacin Pefloxacin Lomefloxacin Difloxacin Sarafloxacin |
| Attribute | Details | Manufacturer Commentary |
|---|---|---|
| Product Name | Enrofloxacin | Enrofloxacin falls into the fluoroquinolone group, commonly produced for veterinary antimicrobial applications. The manufacture requires strict raw material quality, with careful selection of precursors affecting the final impurity profile and suitability for downstream use in injectable, premix, and oral formulations. |
| IUPAC Name | 1-cyclopropyl-7-(4-ethylpiperazin-1-yl)-6-fluoro-4-oxoquinoline-3-carboxylic acid | The IUPAC designation is referenced throughout international regulatory filings. Batch registration for APIs in certain markets hinges on the declared IUPAC structure matching documentation submitted to health authorities. |
| Chemical Formula | C19H22FN3O3 | This formula sets the baseline for raw material balancing and stoichiometry in reactor charge sheets. Production routes and scale adjustments cross-check against this reference to manage yield and expected byproduct management. |
| Synonyms & Trade Names | Baytril, Enrocin, Flobac, Quinocyl, Proflox, Eflocin | Marketing names vary by region, with trade names tied to specific dosage forms or premix types. Process validation for different trade portfolios usually considers both the API physical form and the intent for oral, injectable, or soluble powder use. Technical controls need adjustment for granule, microbead, or solution preparation depending on the end formulation. |
| CAS Registry Number | 93106-60-6 | The CAS number standardizes procurement and quality assurance documentation globally. Our batch traceability system cross-references this identifier for both internal batch tracking and supply chain audit readiness. |
| HS Code & Customs Classification | 2941.90 | This code covers antibiotics from the quinolone family under international customs. For export declaration, trade compliance checks relate documentation to this code; minor differences in customs interpretation regionally can result, as veterinary APIs are sometimes listed distinctly. Consultation with logistics and regulatory teams aligns declared classification with each shipment batch log to minimize customs delays or misclassification disputes. |
API specifications for Enrofloxacin vary depending on the target geography and intended formulation. Markets with strict veterinary drug oversight request additional residual solvent and heavy metal control. For injectable-grade materials, finer particle sizing and higher purity are forced in the crystallization and drying steps. In feed-grade or bulk oral formulations, some process impurities are tolerated at slightly higher levels, provided they do not compromise stability or functional efficacy in the target matrix.
Process routes reflect available starting materials and solvent compliance with local and customer standards. The main impurity sources in enrofloxacin syntheses stem from fluorination and cyclization steps. Switching to lower-residual solvents or continuous purification can address solvent residue carryover; batch-to-batch consistency remains tightly linked to control around those steps. In-process monitoring verifies both yield and impurity rejection, with HPLC and wet-chemistry tests tied to lot release criteria. Release standards refer to both customer-specified COA parameters and product-specific regulatory requirements.
Enrofloxacin’s physical consistency and handling in production plants are grade-specific. API intended for direct compression premixes usually receives secondary particle treatment. For formulations requiring high dispersibility, particle size control during micronization is necessary. Packaging design addresses required moisture and light protection, with packaging material qualified by stability test data. Release to distribution occurs only after internal and customer-mandated QC testing confirms compliance with agreed storage and transport profiles.
Industrial batches of enrofloxacin routinely present as a white to light yellow crystalline powder. Color and minor odor traces vary depending on the intermediate purity and finishing steps. Melting point shows minor lot-to-lot variation, typically observed during initial batch release testing. As a fluoroquinolone, enrofloxacin does not exhibit a well-defined boiling point due to decomposition at elevated temperatures. Density fluctuates with particle morphology—often controlled during milling and drying.
Batch stability varies with respect to exposure to high temperature, humidity, and photolysis. Reactivity concerns center around acid/base-catalyzed degradation and photochemical breakdown, which drive container and storage protocol choices. For sensitive process lines or export markets, stability data is generated under ICH or region-specific storage conditions.
Enrofloxacin's solubility in water remains limited under neutral pH but can increase under acidic or alkaline conditions. This affects both in-process cleaning and downstream application, especially for injectable and oral veterinary formulations. Dissolution rate is influenced by crystal size, surface area, and grade—requiring a tailored dissolution protocol per formulation use scenario.
Release specification varies by intended market and dosage form. Veterinary pharmaceutical grades are generally set for a defined API assay, water content, particulate matter, and clarity for solutions, aligning with pharmacopeial standards where referenced by customer. Different impurity and microbiological limits are applied for finished drug and intermediate grades. Custom lots may include additional parameters based on regional registration demands.
Process-derived impurities originate during key coupling, cyclization, and halogenation steps. Microbiological considerations come into play when the batch is destined for parenteral-grade APIs. Recognized related substances and degradation products depend on the specific synthesis route, and their presence underlines the importance of routine HPLC or UPLC profiling. Final impurity acceptance limits align with customer specification or local regulatory dossiers.
Analytical control employs chromatographic (HPLC), spectroscopic (UV/IR), and titrimetric methods. Specific test protocols are determined by internal QC and, when available, harmonized pharmacopoeial monographs. Process control or rapid methods may be deployed in-process as trending tools but release always refers to validated end-point analytics.
Key starting materials include proprietary fluoroaromatic intermediates, piperazine derivatives, and selected activating agents. Supplier qualification hinges on consistency, trace impurity profile, and regulatory compliance; batch traceability and impurity carry-over must be validated.
The typical route involves nucleophilic substitution and condensation reactions between a fluorinated carboxylic acid derivative and piperazine. Route selection is driven by cost, regulatory acceptance, environmental load, and impurity control. Catalysts and solvents are chosen for reactivity balance and ease of recovery.
Critical control points include temperature regime, pH adjustment, and solvent exchanges. By-product minimization is managed through optimized stoichiometry and continuous in-process impurity monitoring. Crystallization and filtration approaches are tuned to maximize product purity before final drying. Use of robust purification reduces downstream reprocessing and waste.
Each lot’s compliance with in-house and customer specification forms the basis for release. Batch records document the entire production cycle, and every analytical parameter is subject to trending review. No material is released until all critical quality attributes are fully met per product and customer registration files.
Enrofloxacin accepts common modifications, such as salt formation or esterification, for specialized formulations. Its piperazine nitrogen and carboxyl functionality make it amenable to a range of derivatizations, primarily for solubility and pharmacokinetic adjustments in veterinary medicine.
Process conditions depend on solvent, base, acid, and required selectivity. For mainline synthesis, controlled heating in polar solvents under inert atmosphere minimizes unwanted side reactions. Post-synthesis modifications often require water-miscible or aprotic solvents and range of pH management.
Enrofloxacin serves as a precursor for various salts and esters; these downstream forms respond to formulation, administration route, and patent landscapes. Each modification pathway is assessed for impurity risk, by-product formation, and cross-contamination potential within multipurpose plant settings.
Enrofloxacin powder requires storage away from light and moisture sources, typically managed in HVAC-equipped bulk stores. Packaging includes materials with sufficient barrier properties to avoid humidity ingress and photoreaction. Internal stability programs verify suitability of multilayer bags, drums, or high-density polyethylene containers by grade.
Container selection focuses on chemical compatibility and physical protection against breakage, contamination, and environmental challenge. Polyethylene and polypropylene remain standard for primary containment, unless specialty form-fills dictate otherwise. Rigorous clean-down protocols and lot segregation apply.
Shelf life depends on both the manufacturing process and storage chain. Batch testing under accelerated and long-term conditions feeds into expiry date setting. Degradation typically visualized as color deepening, odor shifts, or loss of assay during stability monitoring. Secondary parameters like moisture gain and impurity profile shifts are regularly trended.
Classification and labeling draw from region-specific implementation of GHS, taking into account known acute oral and dermal toxicity together with environmental persistence. Blank statements are avoided in favor of direct referencing local regulatory output when supplied.
Production staff rely on substance-specific hazard profiles, primarily addressing respiratory, eye, and skin exposure risks. Precautionary actions include full PPE, local exhaust ventilation, and controlled transfer engineering. Hazard communications are updated as regulatory and toxicology scholarship evolves.
The toxicological profile is determined in part by active pharmaceutical ingredient standards adapted for worker and environmental safety in the manufacturing domain. Occupational exposure limits reflect current regulatory guidance or absence thereof. Material handling follows corporate protocols which integrate audit findings and root cause analyses from any past excursions or environmental incidents.
In the context of enrofloxacin production, capacity and output depend directly on the installed reactor volume, process step-throughput, process yield, and site-specific compliance for veterinary APIs. Capacity is often affected by license restrictions, environmental control requirements, and campaign scheduling relative to other fluoroquinolone APIs. Availability of final product batches is shaped by upstream raw material procurement—particularly key starting materials and fluoroquinolone intermediates. Interruptions in global supply chains, especially for fluoroquinolone intermediates sourced from China and India, can influence slot availability on short notice. Site flexibility for batch campaigns allows reallocation between veterinary and human API lines based on market demand signals.
Lead times reflect batch synthesis duration, quality assurance turnaround, and logistics constraints. For enrofloxacin, lead times are longest when regulatory submission samples or full validation batches are required; routine commercial orders drawn from production campaigns can meet shorter delivery windows, dependent on stock status. MOQ aligns with economic packing and campaign batch size: technical grades used for premix or bulk formulation will have a higher MOQ than small-pack or high-purity GMP-controlled lots intended for high-value markets.
Packaging is closely linked to grade and end-use. Standard options include fiber drums with double PE liners for industrial consignees, custom semi-bulk bags for premix manufacturers, or tamper-evident bottles for laboratory validation batches. Pharmaceutical-grade orders, especially those requiring EU or US regulatory compliance, will call for detailed packaging validation, secondary containment, and serialized tracking in line with GDP standards.
Terms can be negotiated based on volume, geography, and client-specific requirements. Bulk shipments to integrated premix or formulation plants generally move by sea in containerized freight with temperature controls when required. Airfreight may be considered for urgent, high-grade orders, with cost implications. Payment terms shift according to customer commercial history, contract structure, and region. Export controls, documentation, and LC terms can extend lead time for high-regulation destinations.
Raw material sourcing for enrofloxacin is the single largest driver of direct manufacturing cost. Consistency in this area is challenged by the limited number of qualified suppliers for key intermediates and the volatility of precursor chemicals, some of which are subject to periodic export controls and environmental shutdowns, particularly from China.
Fluctuations reflect shifts in crude raw material costs (fluorinated chemicals, piperazine derivatives), as well as regulatory actions affecting intermediate plants. Cost drivers also include energy prices and compliance costs for environmental abatement. Unplanned shutdowns or regulatory inspections at upstream chemical producers, especially in Zhejiang and Jiangsu provinces, often send ripples through the market, amplifying price swings.
The sale price of enrofloxacin is set by multiple factors, not a single market quote. Certification status (GMP, CEP, DMF registration), batch-to-batch purity level, and compliance documentation all play a central role. Veterinary feed additive grades permit broader impurity profiles and may employ commercial-grade intermediates, while injectable grades require high-purity, narrow impurity windows, and full traceability.
Packaging requirements, including serialization and anti-tamper measures, introduce additional costs for regulated markets. Each level of certification and compliance raises COGS from material selection to release testing. Lower price quotes generally reflect less rigorous quality documentation, less stringent process controls, or supply from non-registration lots.
Enrofloxacin, designed for veterinary use, responds to demand shifts in animal health, particularly poultry, swine, and aquaculture sectors. Asia and Latin America account for much of the volume market, while the EU and US regulate use more tightly and support only higher-purity, certified lots. Supply bottlenecks are typically upstream and tied to intermediate production disruptions.
United States: Market favors high-purity, fully documented batches. Product import is subject to strict regulatory review, limiting the number of qualified sources.
European Union: Volume is controlled through regulatory restrictions. API must comply with relatively narrow impurity ceilings and comprehensive registration dossiers.
Japan: Tightly managed through a registration system. Market has lower volume but demands high compliance.
India: Domestic consumption dominates bulk and technical grades. Regulatory environment is evolving, but market still tolerates a broader impurity profile, especially for feed-use.
China: Largest production base, both for domestic use and global supply. Regulatory interventions to address environmental controls can directly affect global availability and price trends.
Price trends will remain sensitive to unpredictable regulatory and supply-side events. With ongoing consolidation in intermediate supply and tightening of environmental compliance in key production regions of China and India, expect cost-push inflation for feed and technical grades. Premium will widen further for regulatory-compliant, high-documentation lots shipped to Europe, the US, and Japan as compliance costs rise. Downward price movement appears unlikely barring a significant shift in intermediate manufacturing technology or relaxation in global regulatory standards.
All interpretations are grounded in internal procurement logs, customer demand tracking data, regional regulatory bulletins, and third-party industry analytics. Price and supply projections synthesize in-house production data and observable upstream raw material trends from verified trade sources.
Recent capacity reductions in intermediate plants have impacted both lead times and price offers for technical and premium grades. Output reallocation for regulatory-compliant lots has grown in response to tightening import scrutiny, particularly in the EU and US.
Veterinary application restrictions in major economies have gradually shifted global demand toward grades carrying full regulatory documentation. Manufacturers operating at the GMP/API grade level, as well as those holding CEP, DMF, or equivalent certifications, face increased inspection frequency and document audit depth. Evidence of enhanced impurity profile documentation is increasingly required at the border and post-shipment audit stages.
To stabilize cost and minimize disruption, risk management now places greater emphasis on dual sourcing and strategic supply chain partnerships, particularly for sensitive intermediates. In-process control adapts to variability in upstream shipments by reinforcing incoming quality checks and dynamic campaign scheduling. Future supply agreements increasingly build in contingencies for regulatory or environmental action affecting component availability.
Enrofloxacin plays a central role in the veterinary pharmaceutical sector, particularly in the formulation of products for livestock and companion animals. Its main uses center around the prevention and treatment of bacterial infections in poultry, cattle, swine, and aquaculture systems. Strict regulation in food-producing animal use drives different manufacturing controls and purity profiles for each segment.
Outside of veterinary therapeutics, some regions examine enrofloxacin’s utility in research and diagnostic settings, primarily under strictly monitored circumstances. All applications require precise impurity and residue control to limit carryover into animal products and ensure compliance with local regulations.
| Application | Typical Grade | Key Quality Considerations |
|---|---|---|
| Oral Formulation (Premix, Soluble Powder, Tablet) | Pharmaceutical Grade | Purity, Residual Solvents, Particle Size, Moisture Content, Microbiological Load |
| Injectable Formulation | Parenteral Grade | Endotoxins, Heavy Metals, Sterility, Solubility Profile, Trace Impurities |
| Aquaculture Appl. | Veterinary Grade / Customized Grade | Solubility, Particle Size, Residual Organic Acids, Compound Stability under Alkaline Conditions |
| Diagnostic or R&D Use | Research Grade | Defined on project basis, may involve looser controls unless downstream use requires pharmaceutical compliance |
For oral premixes and powders, flowability and particle size distribution are points of focus. Finer grades favor suspension and even dosing; excessive particle size variation leads to stratification or clogged feeders. Batch-to-batch reproducibility is critical due to direct impact on dosing uniformity. Residual solvents and process-related impurities draw closer scrutiny for feed or parenteral applications, especially given that administration bypasses gut metabolism.
Injectables demand rigorous control over endotoxin content and low bioburden. Sterile filtration or terminal sterilization will depend on formulation requirements. In regions with stricter veterinary drug controls, heavy metal content and specific impurity profiles steer selection of raw materials and impact purification stages.
In aquaculture, product must withstand water dispersal and maintain efficacy through potential pH variation, salinity, and organic load. This means more emphasis on solubility testing under simulated field conditions, and the need for a stable formulation that avoids visible precipitation.
Start by pinpointing intended use—species, administration route, and dosage form. Deciding early saves time and avoids regulatory setbacks, as different endpoints will warrant separate control strategies during batch manufacture.
Compliance guidance changes by country and animal species. Veterinary applications involving food animals usually run under more restrictive frameworks than companion animal routes. Some authorities request formal drug master file submissions; others allow simplified dossiers for non-food use. Manufacturing protocols and documentation should stay aligned with expected submission needs.
Review the impurity and residual solvent thresholds applicable for your finished product. Pharmaceutical and parenteral grades tighten allowable ranges on process contaminants, organics, and particulate matter. Our facility segregates synthesis lines and customizes purification protocols to align with each customer's risk profile.
Order volume affects production scheduling and batch sizing decisions. High-volume feed applications often allow for some process economy, whereas ultra-low impurity grades for parenterals carry greater raw material and labor costs. Cost-performance analysis should be based on both total active content and impurity-release profile.
Applications with unique carrier systems or device compatibility concerns benefit from pilot-scale sample runs. Customers supply target specifications and, upon request, our technical team prepares batches that mimic planned commercial scale-up. Feedback from these validation trials supports robust quality agreements and minimizes supply interruptions.
Quality management frameworks guide our entire operation. Site and system certifications reflect real inspection and validation from recognized authorities, including ISO 9001 and system audits required by veterinary pharmaceutical laws in the regions where customers operate. Our technical team maintains documentation of auditor findings and process improvement steps. Regular reviews of supplier documentation, traceability records, and change control logs provide the backbone for both everyday manufacturing and formal compliance checks. Different markets prompt additional documentation; for example, batch traceability requirements in the EU or supplemental records for export to Latin American customers.
Product-grade certifications depend on the application domain. Veterinary-use APIs comply with relevant pharmacopoeial monographs—such as Ph. Eur., USP, or national standards—according to supply agreement. Typical grade distinctions address solubility, particle size, residual solvent levels, and limits on related substances as set by customer order or regulatory filings. Certificates of Analysis, GMP compliance declarations, and Drug Master File (DMF) cross-references are issued batch-wise for regulated markets. Third-party audit reports for site or process reviews are also available under NDA if needed for regulatory submissions.
Every batch release generates documentation packages, including analytical data, raw material origin statements, and process deviation reports, if applicable. Stability data, retention sample tracking, and ongoing process monitoring records are archived in secure, standardized systems. Custom reporting, such as impurity profile breakdowns or additional microbial testing, can be arranged for specialized applications or regulatory projects. Each customer receives documentation geared to their grade, downstream process, and market legislation.
Consistent output starts at raw material contracts. We establish buffer stock of starting materials and maintain audited alternative suppliers to mitigate disruption risks. Plant schedules reserve baseline capacity for ongoing clients while allowing contingency runs for urgent orders or market shifts. Flexibility covers shipment formats (drums, sacks, bulk), frequency, volume, and documentation delivery. Business terms adjust based on port of dispatch, regulatory pre-shipment releases, and preferred shipping routes.
Production facilities rely on controlled environment synthesis lines, with capacity defined by actual finished API output per quarter. Key control points in synthesis and purification, along with high-precision volumetric equipment, ensure that each order is matched to specification and supply schedule. Monitoring of in-process controls—like reaction purity or moiety conversion—guides batch release and reduces variability between supply lots. Stability of physical properties (such as humidity sensitivity of the API) directs packaging choices and shipping conditions based on customer’s region and transit time.
Sample requests are processed through a technical vetting channel; requestors confirm end use, grade needs, and integration environment. Each sample ships with supporting documentation, including preliminary COA reference, material handling advice for pilot-lab, and contact information for direct technical consultation with production supervisors. Test metrics provided depend on intended downstream use; any additional application-specific tests require pre-approval and can extend lead time.
Cooperative models depend on customer needs: fixed-term contracts lock in price and quantity for large-volume users, while project-based engagement suits development pipelines with uncertain scaling. Split-shipment arrangements help downstream processors minimize warehouse overhead and synchronize delivery with formulation schedules. For multi-region buyers, we handle differentiated documentation packages according to regional regulatory demands. Technical liaison teams coordinate change notifications, specification adjustments, or custom packaging for each cooperation framework.
Technical teams across the sector currently scrutinize strain specificity, resistance profiles, and synthesis yield improvement in the production of enrofloxacin. Emphasis falls on minimizing process-related impurities, particularly those affecting pharmacopoeia compliance for animal health markets. Raw material origin, water content of intermediates, and pH stabilization at each key stage receive direct monitoring due to their influence on impurity profiles and batch repeatability. End-users increasingly request documentation supporting trace contaminants and process-derived residuals, which drives tighter quality management systems within manufacturing facilities.
As a fluoroquinolone veterinary active, enrofloxacin sees application shifts toward more targeted formulations, such as long-acting injectables and slow-release intramammary products. Compound demand now often arises from combination drug premixes and custom dosing preparations, with formulators expecting detailed physico-chemical data to support new delivery technologies. Recent inquiries focus on compatibility testing with excipients and co-formulated antimicrobials, reflecting greater regulatory scrutiny and a push for single-dose interventions.
Key challenges involve achieving low impurity levels with consistent batch reproducibility, especially as global limits on fluoroquinolones in food-producing animals tighten. Synthesis engineers prioritize control over halogenated intermediates and waste stream mitigation at the step introducing the quinolone skeleton, as these remain primary sources of process complexity. Crystallization and post-synthesis drying steps influence residual solvent outcomes; optimizations here have recently produced more robust downstream granule characteristics, which feed directly into tablet pressing and injectable formulations. Experience has shown that flow properties and filterability are acutely sensitive to tiny shifts in final purification solvent ratios—these lessons now shape our standard protocols.
While demand for enrofloxacin aligns closely with agricultural trends and regional policy movements, current consensus supports steady to modest growth, especially in markets with evolving veterinary infrastructure. The expansion of poultry, aquaculture, and ruminant industries in certain regions sustains base volume requirements. Market volatility arises from ongoing regulatory debates and periodic changes in allowable residue levels. Future procurement by large premix manufacturers often depends on demonstrated supply chain transparency and auditability.
The evolution of synthetic routes for enrofloxacin tends to favor lower-waste and more energy-conscious operations. Process engineers now select precursor routes not only based on cost but on byproduct stream minimization and inclusivity of recycling loops for halogenated solvents. Emphasis on inline process analytics grows: real-time detection of off-spec byproducts during key coupling reactions translates into more consistent final purity. Batch record digitalization and automation enter greater use, aiming to cut operator error and reduce cross-contamination risk, especially for export-compliant grades.
Production management recognizes solvent selection, waste treatment, and non-halogenated alternatives as central elements of sustainability. Specific attention targets the environmental fate of intermediate and waste streams, as both regulatory frameworks and local consent requirements set stricter discharge thresholds. Research pilots now increasingly trial solvent recovery, closed-loop cooling, and energy-saving reactor designs. Batch tracking extends to carbon emission accounting at the level of raw material transport and process energy usage.
Every major enrofloxacin output is paired with consultative support from process and analytical chemists familiar with route-specific impurity questions, formulation approaches, and regulatory landscapes. Analytical teams assist in technical discussions regarding method validation, impurity profiling, and batch-to-batch traceability for audit purposes. For end users transitioning between grades or suppliers, support covers full equivalence documentation and risk assessment of switching.
Formulation specialists work with partners on dissolution rate studies, excipient compatibility, and shelf-life extension inquiries tailored to the application-grade supplied. Customers with unique application routes (such as injectables or suspension premixes) receive case-by-case technical advice fitting their process requirements. As each downstream process—from granule blending to sterile filtration—imposes specific demands on the active, technical support takes into account both the pharmacological and process engineering context.
Commitment to after-sales support centers on prompt investigation of any off-spec reports, traceability of each batch, and rapid feedback cycles for corrective action. Quality control tracks not only specification compliance but customer-identified critical parameters, such as physicochemical changes during formulation or storage, so support remains application-sensitive. Release testing and documentation are tailored per customer and regulatory authority requirements, with technical teams ready to clarify results and undertake special investigations on request. Internal systems log and review every deviation and complaint as part of ongoing process improvement and customer assurance.
As a direct manufacturer of enrofloxacin, our commitment centers on producing a high-purity active pharmaceutical ingredient with lot-to-lot consistency for veterinary health applications. Our continuous investment in process technology and in-house quality control has shaped our reputation among established pharmaceutical producers and feed additive formulators.
Enrofloxacin production at our facility takes place in dedicated synthesis lines. These lines use validated procedures from raw material qualification to crystallization and final isolation, which prevents cross-contamination and avoids batch variability. We establish critical control points along the production route—testing both starting materials and intermediates as the synthesis progresses.
Most of the enrofloxacin we supply supports significant projects in veterinary medicine manufacturing. Our partners formulate it into injectable solutions, oral suspensions, and premixes for commercial livestock and poultry farms. Large-scale aquaculture operators also use enrofloxacin-based treatments to maintain stock health. The tightly controlled impurity profile of our product enables reliable downstream formulation without reprocessing or additional purification steps. This reduces production lead times and overhead for our customers.
All material leaving our site meets specifications established for pharmaceutical use. Each lot undergoes full-spectrum analysis, including chromatographic identification of related compounds, water content checks, residue on ignition, and particle size assessment. Our lab team runs microbiological assessments to demonstrate the absence of endotoxins. This approach supports regulatory documentation and ensures consistency for integration into registered formulations.
We offer enrofloxacin in industrial-scale fiber drums and tamper-evident PE liners, with multiple packaging options to fit different loading and storage setups. Our logistics team controls warehouse release, export handling, and documentation, which preserves traceability and expedites customs clearance for international buyers. Regular contract customers rely on our just-in-time shipment schedule to support their production forecasts.
Clients regularly engage with our chemists for technical discussions such as validating analytical protocols, evaluating compatibility with excipients, or planning pilot runs after process scale-up. Over the years, our technical collaboration with plant managers and R&D formulators has helped resolve production bottlenecks and facilitated regulatory submissions in multiple jurisdictions. We maintain a transparent technical dossier and provide guidance on product handling from receipt through formulation.
| Benefit Area | How We Deliver |
|---|---|
| Product Performance | Secured through complete production oversight and robust QC procedures. |
| Regulatory Documentation | Comprehensive compliance support with full batch analysis reports and process transparency. |
| Supply Assurance | Flexible, scalable manufacturing volumes and predictable logistics. |
| Collaborative Support | Direct engagement with our technical and production experts for formulation and troubleshooting. |
Long-term partnerships with veterinary pharmaceutical producers and animal feed manufacturers rely on the stable foundation provided by direct enrofloxacin production. Our team addresses every stage from synthesis through technical support, ensuring that procurement professionals and supply chain managers achieve both compliance and efficiency with each delivery.
Every year, veterinarians rely on Enrofloxacin to help safeguard the health of livestock, poultry, and companion animals. Our manufacturing team remains deeply involved in formulation and continuous quality control of this active compound so veterinary practitioners can expect consistent performance. Enrofloxacin, a synthetic fluoroquinolone, operates through a direct interference with bacterial DNA processes. Specifically, it binds to the bacterial enzymes DNA gyrase (topoisomerase II) and topoisomerase IV. Bacteria depend on these enzymes to replicate, transcribe, and repair their genetic material.
By interfering with DNA gyrase, Enrofloxacin induces breaks in the DNA strands, ultimately causing bacterial cell death. This mode of action makes it a reliable bactericidal agent, not merely inhibiting growth but actively reducing pathogen populations. It shows concentration-dependent killing, meaning higher drug levels in targeted tissues result in a more pronounced sterilizing effect. Our technical team tailors manufacturing protocols to deliver a product with stable pharmacokinetic characteristics so animal health outcomes remain predictable across veterinary practice settings.
The strength of Enrofloxacin lies in its broad spectrum of activity against both Gram-negative and certain Gram-positive bacteria. Our regular batch analysis confirms the in vitro potency against bacteria that frequently challenge livestock: Escherichia coli, Salmonella spp., Pasteurella multocida, Actinobacillus pleuropneumoniae, Staphylococcus aureus, and Mycoplasma species. It also shows activity against Bordetella bronchiseptica, a pathogen of respiratory significance in swine and dogs.
This range offers veterinarians a reliable option when faced with infections such as respiratory tract illnesses, urinary tract infections, or wound infections caused by susceptible organisms. Across our production facilities, we perform routine microbial susceptibility testing to track any trends which may suggest rising resistance. Direct cooperation with veterinarians keeps us aligned with field observations and influences our production decisions as part of our commitment to antimicrobial stewardship.
Antimicrobial resistance has become a top concern for responsible manufacturers. Decades of clinical use have demonstrated that correct dosing and compliance with withdrawal periods help safeguard both animal health and food safety. Our production guidelines strictly follow these best practices, with every batch subject to residue testing and traceability protocols. We provide technical guidance to clients to promote rational use, helping delay resistance development in target bacterial populations.
Veterinary professionals continue to encounter evolving resistance mechanisms, prompting renewed focus on pharmacological surveillance. We contribute by supporting monitoring programs and sharing real-world product performance data with regulatory authorities. Transparency in antimicrobial production and use remains essential to keep therapies effective for future generations.
As a manufacturer, we recognize that animal health and food safety rely on rigorous science, direct technical support, and continual investment in quality. Enrofloxacin remains part of our veterinary pharmaceutical portfolio because experience and global research support its controlled, evidence-based use. Our team remains available to provide further guidance or product information for responsible practitioners.
Drawing from our experience as a direct manufacturer of veterinary-grade enrofloxacin, customers and partners often want to know about the packaging options and order requirements before their project planning begins. In the field of animal health, safe, effective treatment hinges on material quality, but logistics and supply stability play just as large a role. We account for these realities during every stage of our production and packaging process.
Enrofloxacin produced at industrial scale arrives in packaging designed for ease of handling during shipping, storage, and usage in both small and large veterinary operations. For powder and granular forms, our product typically leaves the plant in high-integrity fiber drums with polyethylene liners. Standard drum sizes remain 25 kilograms per drum, as this format matches the requirements encountered across feed additive manufacturing, formulation plants, and animal health companies. Smaller pack sizes create unnecessary handling and material loss risks in most of our core applications, while oversized units rarely meet the batch sizes of key partners. Liquid forms of enrofloxacin are filled into high-density plastic drums or intermediate bulk containers as required by the transport profile and destination regulations.
We manufacture our enrofloxacin to strict quality standards, with all packaging conducted in GMP-compliant, controlled filling zones. Every packaging unit receives a label indicating batch traceability, date of manufacture, and a QR code with digital access to certificates of analysis. This focus on robust packaging ensures the compound’s stability during ocean freight or prolonged warehouse storage — a lesson we learned long ago during early export projects when chemical degradation occurred in substandard packaging. Through direct conversations with end users, we have heard repeatedly that the extra care we invest in packaging integrity prevents costly issues and reinforces confidence in supply.
For enrofloxacin, a typical minimum order quantity stands at one full drum, or 25 kilograms. This threshold is calibrated to the realities of production line efficiency and international delivery costs. Any reduction in order size translates into higher unit costs, more packaging waste, and elevated risks of contamination. Orders below a single drum do not support the streamlined, contamination-controlled production approaches we use to keep our products at scale. For bulk buyers, we load full container loads — a choice that cuts both per-kilogram cost and delivery risk.
Through ongoing dialogue with our partners, we find that 25 kg drums meet requirements for both regular program supply and pilot-phase evaluation, whether destined for established European feed mills or emerging market distributors. Our operations team offers scheduling flexibility for annual contracts to secure predictable pipeline flows. If special project requirements arise, our technical and commercial managers work together to review custom proposals, though experience shows that the 25 kg minimum order remains the reference point for efficiency and reliability from production floor to field application.
By keeping packaging and minimum order strategies closely aligned with proven supply chain results, we commit to quality, transparency, and responsiveness. Our technical team’s door is always open for supporting partners with product documentation, customized solutions, or logistical guidance. Years of direct manufacturer experience led us to design these protocols; we see that stable packaging and sensible order sizing minimize risks, control costs, and drive sustained value for both new and long-term clients.
Discussions around Enrofloxacin rarely ignore the evolving landscape of local import regulations. In our experience manufacturing veterinary pharmaceuticals, every country brings its unique scrutiny to antimicrobial agents, and Enrofloxacin stands among those compounds under close watch. Regulatory authorities such as the US FDA, EU EMA, and China’s Ministry of Agriculture impose a detailed dossier review focusing on active ingredient identification, purity levels, intended use, and user safety. Our quality management ensures every batch leaves our factory with verifiable certificates of analysis, traceable batch records, and validated manufacturing processes. Authorities often request GMP certification, audit reports, and occasionally a prior on-site inspection before shipment approval. We recognize that regulatory compliance grows stricter each year, especially regarding importation, usage, and final market approval, reflecting an international commitment to protect animal and, by extension, public health.
In practice, local documentation requests vary. We routinely provide material safety data sheets, product registration dossiers, and official export permits. Import license requirements, language-specific labelling, and prescribed shelf life documentation often challenge new partners. Experience tells us the best compliance record comes from direct communication with local regulators and dedicated regulatory affairs specialists on our team. Our staff answers technical questions, resolves document gaps, and delivers what custom authorities demand – and we document every step. Regulatory compliance doesn’t end with batch testing; it follows each shipment down to the last box.
Maintaining Enrofloxacin’s quality during transit starts at the production plant. Our active ingredient and formulated products leave our site in sealed, light-resistant containers designed to prevent moisture ingress and chemical degradation. Temperature control earns special attention. We ship standard grades of Enrofloxacin under conditions that maintain temperatures between 15°C and 30°C. Deviations above or below this range risk hydrolysis or oxidative loss, potentially resulting in off-specification material by the time it reaches the end user.
Because international transit exposes goods to temperature swings, our logistics partners use insulated pallets, thermal blankets, and, for longer hauls or hot climates, refrigerated containers. These choices depend on destination, season, and expected transit duration. We document container loading with time-stamped digital photos, issue tamper-evident seals, and record temperature data throughout the journey, including data logger reports on request. If import runs by ocean freight, container selection includes evaluation of vessel’s cold chain compliance. Any compromise in these measures can lead to regulatory non-compliance, product rejection, or delayed clearance at ports.
As a factory-direct producer, our primary responsibility is to anticipate regulatory questions and storage threats before goods ever leave our control. We offer local regulatory support, comprehensive shipping documentation, and arrange pre-shipment inspections if a destination authority requests it. All specifications, batch quality certificates, and storage handling recommendations are available for review before purchase orders are confirmed. Our technical support team helps distributors, formulators, and end users navigate changing rules around antibiotics such as Enrofloxacin and delivers real-time advice if standards shift or new paperwork emerges mid-application.
In the end, ignoring local regulations or neglecting suitable shipping standards causes bigger problems than minor delays. By proactively engaging regulators and investing in proper packaging and logistics planning, we see fewer border holdups, less wastage, and consistent customer satisfaction from batch to batch and country to country. As rules and technology advance, our direct manufacturing approach keeps the customer’s risk as low as possible, no matter where Enrofloxacin travels next.
For product inquiries, sample requests, quotations or after-sales support, please feel free to contact me directly via sales3@ascent-chem.com, +8615365186327 or WhatsApp: +8615365186327
